Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) and Evofem Biosciences (NASDAQ:EVFM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Profitability
This table compares Chemomab Therapeutics and Evofem Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Chemomab Therapeutics | N/A | -101.70% | -76.18% |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
Risk and Volatility
Chemomab Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.87, meaning that its stock price is 187% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Chemomab Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Evofem Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Chemomab Therapeutics currently has a consensus target price of $9.00, indicating a potential upside of 650.00%. Given Chemomab Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Chemomab Therapeutics is more favorable than Evofem Biosciences.
Insider & Institutional Ownership
46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Chemomab Therapeutics and Evofem Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Chemomab Therapeutics | N/A | N/A | -$24.22 million | ($0.90) | -1.33 |
| Evofem Biosciences | $11.39 million | 0.09 | $52.98 million | ($0.21) | -0.05 |
Evofem Biosciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Chemomab Therapeutics beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
